BioWorld

Oct. 29, 2002

Dendreon Gets OK To Resume Enrollment In Phase III Study

Following a six-month delay, Dendreon Corp. received FDA clearance to resume enrollment in its second Phase III trial of Provenge, a therapeutic vaccine for hormone-resistant prostate cancer patients. (BioWorld Today) Read More

Peninsula Raises $22.1M To Fund In-Licensing Program

NIH Scientists Report Finding New Deafness Gene, Mucolipin By Name, Joining Worldwide Panoply Of Same

Abbott's Humira Continues To Impress In RA Treatment

Other News To Note

Correction

Endo's Second Phase III For MorphiDex Misses Endpoint

Aphton Reports Phase III Results Showing G17DT Extends Survival

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...